| Literature DB >> 30616753 |
Sreejit Parameswaran1, Deeksha Kundapur1, Frederick S Vizeacoumar2, Andrew Freywald3, Maruti Uppalapati4, Franco J Vizeacoumar5.
Abstract
Targeted therapies rely on the genetic and epigenetic status of the tumor cells and are seen as the most promising approach to treat cancer today. However, current targeted therapies focus on directly inhibiting those molecules that are altered in tumor cells. Unfortunately, targeting these molecules, even with specific inhibitors, is challenging as tumor cells rewire their genetic circuitry to eliminate genetic dependency on these targets. Here, we describe how synthetic lethality approaches can be used to identify genetic dependencies and develop personalized targeted therapies. We also discuss strategies to specifically target these genetic dependencies, using small molecule and biologic drugs.Entities:
Keywords: shRNA vs CRISPR; synthetic lethality; targeting intracellular molecules
Mesh:
Substances:
Year: 2018 PMID: 30616753 DOI: 10.1016/j.trecan.2018.11.001
Source DB: PubMed Journal: Trends Cancer ISSN: 2405-8025